Quick Search
Retrospective evaluation of amniocentesis results: A tertiary center data
Mustafa Bağcı1, Kazım Uçkan1, Hanım Güler Şahin1, Onur Karaaslan2, Yusuf Başkıran2, Erbil Karaman31Division of Perinatology, Department of Obstetrics and Gynecology, Van Yuzuncu Yil University Faculty of Medicine, Van, Turkey2Department of Gynecology and Obstetrics, Van Yuzuncu Yil University Faculty of Medicine,Van, Turkey
3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Van Yuzuncu Yil University Faculty of Medicine, Van, Turkey
INTRODUCTION: The aim of this study is to contribute to the literature by retrospectively analyzing the indications, results, culture successes, and pregnancy results of patients who underwent amniocentesis in our clinic between 2021–2022.
METHODS: Our study includes the results of 132 patients who underwent amniocentesis. Demographic characteristics, weeks of gestation, amniocentesis indications, results, complications, and pregnancy outcomes of the patients were evaluated.
RESULTS: In our study, the most common indication for amniocentesis was patients with fetal anomaly detected in ultrasonography (US) with a rate of 38.6% (51/132). The culture success rate was 98.5%. Chromosome anomaly was detected as 18.2% (24/132) in the culture results. Chromosome anomaly was found in 15.7% (8/51) of patients with a fetal anomaly in US. The most common numerical anomalies in culture were Trisomy 21 and Trisomy 18. Among the chromosomal microarray analysis (CMA) results, 4.9% (2/41) were found to be pathogenic and 4.9% (2/41) were classified as variants of uncertain significance (VUS). The pregnancy of 13 patients with chromosomal anomalies was terminated, and three had stillbirths. No maternal or fetal complications related to amniocentesis were observed.
DISCUSSION AND CONCLUSION: Amniocentesis is a reliable and successful prenatal diagnosis test. The results of our study can provide a database for the literature to provide appropriate genetic counseling.
Manuscript Language: English
